Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover

Bone

Volumn 57, Issue 1, 2013, Pages 272-276

  Gifre, L ^a   Ruiz Gaspa S ^a   Monegal, A ^a   Nomdedeu, B ^a   Filella, X ^a   Guanabens N ^a   Peris, P ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Dkk 1; Glucocorticoid; Sclerostin; Wnt antagonists

Indexed keywords

ALKALINE PHOSPHATASE; DICKKOPF 1 PROTEIN; OSTEOCALCIN; PREDNISONE; PROCOLLAGEN; PROCOLLAGEN C PROTEINASE; PROCOLLAGEN TYPE 1 AMINOPEPTIDE; SCLEROSTIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BONE DENSITY; BONE TURNOVER; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; FEMALE; FOLLOW UP; HEMOLYTIC ANEMIA; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LUMBAR SPINE; MALE; OSSIFICATION; OSTEOLYSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; TREATMENT DURATION; WNT SIGNALING PATHWAY;

BMD; BMI; BODY MASS INDEX; BONE ALKALINE PHOSPHATASE; BONE ALP; BONE MINERAL DENSITY; DICKKOPF; DKK-1; GCC; GCCT; GLUCOCORTICOID; GLUCOCORTICOID THERAPY; OC; OSTEOCALCIN; P1NP; PROPEPTIDE AMINO-TERMINAL OF TYPE I PROCOLLAGEN; SCLEROSTIN; SCTX; SD; SERUM CARBOXY-TERMINAL TELOPEPTIDE OF TYPE I COLLAGEN; STANDARD DEVIATION OF THE MEAN; WNT ANTAGONISTS;

ADULT; AGED; BONE DENSITY; BONE MORPHOGENETIC PROTEINS; FEMALE; GENETIC MARKERS; GLUCOCORTICOIDS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; OSTEOGENESIS; PROSPECTIVE STUDIES; WNT SIGNALING PATHWAY;

EID: 84883639194     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2013.08.016     Document Type: Article

References (33)

1. Rizzoli R., Adachi J.D., Cooper C., Dere W., Devogelaer J.P., Diez-Perez A., et al. Management of glucocorticoid-induced osteoporosis. Calcif Tissue Int 2012, 91:225-243.
2. van Staa T.P., Leufkens H.G., Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002, 13:777-787.
3. Canalis E., Mazziotti G., Giustina A., Bilezikian J.P. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 2007, 18:1319-1328.
4. Hernandez M.V., Guanabens N., Alvarez L., Monegal A., Peris P., Riba J., et al. Immunocytochemical evidence on the effects of glucocorticoids on type I collagen synthesis in human osteoblastic cells. Calcif Tissue Int 2004, 74:284-293.
5. Xia X., Kar R., Gluhak-Heinrich J., Yao W., Lane N.E., Bonewald L.F., et al. Glucocorticoid-induced autophagy in osteocytes. J Bone Miner Res 2010, 25:2479-2488.
6. O'Brien C.A., Jia D., Plotkin L.I., Bellido T., Powers C.C., Stewart S.A., et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 2004, 145:1835-1841.
7. Bonewald L.F. The amazing osteocyte. J Bone Miner Res 2011, 26:229-238.
8. Li J., Sarosi I., Cattley R.C., Pretorius J., Asuncion F., Grisanti M., et al. Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone 2006, 39:754-766.
9. Pinzone J.J., Hall B.M., Thudi N.K., Vonau M., Qiang Y.W., Rosol T.J., et al. The role of Dickkopf-1 in bone development, homeostasis, and disease. Blood 2009, 113:517-525.
10. Voorzaner-Rousselot N., Goehrig D., Facon T., Clézardin P., Garnero P. Platelet is a major contributor to circulating levels of Dickkopf-1: clinical implications in patients with multiple myeloma. B Br J Haematol 2009, 264-266.
11. Wang F.S., Ko J.Y., Yeh D.W., Ke H.C., Wu H.L. Modulation of Dickkopf-1 attenuates glucocorticoid induction of osteoblast apoptosis, adipocytic differentiation, and bone mass loss. Endocrinology 2008, 149:1793-1801.
12. Mak W., Shao X., Dunstan C.R., Seibel M.J., Zhou H. Biphasic glucocorticoid-dependent regulation of Wnt expression and its inhibitors in mature osteoblastic cells. Calcif Tissue Int 2009, 85:538-545.
13. Thiele S., Ziegler N., Tsourdi E., De Bosscher K., Tuckermann J.P., Hofbauer L.C., et al. Selective glucocorticoid receptor modulation maintains bone mineral density in mice. J Bone Miner Res 2012, 27:2242-2250.
14. Brabnikova Maresova K., Pavelka K., Stepan J.J. Acute effects of glucocorticoids on serum markers of osteoclasts, osteoblasts, and osteocytes. Calcif Tissue Int 2013, 92:354-361.
15. Brunetti G., Faienza M.F., Piacente L., Ventura A., Oranger A., Carbone C., et al. High dickkopf-1 levels in sera and leukocytes from children with 21-hydroxylase deficiency on chronic glucocorticoid treatment. Am J Physiol Endocrinol Metab 2013, 304:E546-E554.
16. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. World Health Organ Tech Rep Ser 1994, 843:1-129.
17. Ohnaka K., Taniguchi H., Kawate H., Nawata H., Takayanagi R. Glucocorticoid enhances the expression of dickkopf-1 in human osteoblasts: novel mechanism of glucocorticoid-induced osteoporosis. Biochem Biophys Res Commun 2004, 318:259-264.
18. Macaulay I.C., Thon J.N., Tijssen M.R., Steele B.M., MacDonald B.T., Meade G. Canonical Wnt signaling in megakaryocytes regulates proplatelet formation. Blood 2013, 121:188-196.
19. Belaya Z.E., Rozhinskaya L.Y., Melnichenko G.A., Solodovnikov A.G., Dragunova N.V., Iljin A.V., et al. Serum extracellular secreted antagonists of the canonical Wnt/beta-catenin signaling pathway in patients with Cushing's syndrome. Osteoporos Int 2013, 24:2191-2199.
20. Gossiel F., Lane N., Eastell R. The effect of glucocorticoid therapy on regulators of bone formation in postmenopausal women treated with teriparatide or alendronate. ASBMR Annual Meeting 2011, S80. [Abstract].
21. Yao W., Cheng Z., Busse C., Pham A., Nakamura M.C., Lane N.E. Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice. Arthritis Rheum 2008, 58:1674-1686.
22. Modder UI, Hoey KA, Amin S, McCready LK, Achenbach SJ, Riggs BL, et al. Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res 2011;26:373-9.
23. Modder UI, Clowes JA, Hoey K, Peterson JM, McCready L, OurslerMJ, et al. Regulation of circulating sclerostin levels by sex steroids in women and in men. J Bone Miner Res 2010;26:27-34.
24. Ardawi MS, Al-Kadi HA, Rouzi AA, Qari MH. Determinants of serum sclerostin in healthy pre- and postmenopausal women. J Bone Miner Res 2011;26:2812-22.
25. Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001;44:202-11.
26. Kaji H, Kuroki Y, Murakawa Y, Funakawa I, Funasaka Y, Kanda F, et al. Effect of alendronate on bone metabolic indices and bone mineral density in patients treated with high-dose glucocorticoid: a prospective study. Osteoporos Int 2010;21:1565-71.
27. Gaudio A, Pennisi P, Bratengeier C, Torrisi V, Lindner B, Mangiafico RA, et al. Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J Clin Endocrinol Metab 2010;95:2248-53.
28. Gatti D, Viapiana O, Adami S, Idolazzi L, Fracassi E, Rossini M. Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin. Bone 2012;50:739-42.
29. Gatti D, Viapiana O, Fracassi E, Idolazzi L, Dartizio C, Povino MR, et al. Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab. J Bone Miner Res 2012;27:2259-63.
30. Hampson G, Edwards S, Conroy S, Blake GM, Fogelman I, Frost ML. The relationship between inhibitors of the Wnt signalling pathway (Dickkopf-1(DKK1) and sclerostin), bone mineral density, vascular calcification and arterial stiffness in post-menopausal women. Bone 2013;56:42-7.
31. Thambiah S., Roplekar R., Manghat P., Fogelman I., Fraser W.D., Goldsmith D. Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness. Calcif Tissue Int 2012, 90:473-480.
32. Polyzos S.A., Anastasilakis A.D., Bratengeier C., Woloszczuk W., Papatheodorou A., Terpos E. Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women-the six-month effect of risedronate and teriparatide. Osteoporos Int 2012, 23:1171-1176.
33. Garnero P., Sornay-Rendu E., Munoz F., Borel O., Chapurlat R.D. Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study. Osteoporos Int 2013, 24:489-494.